目的 探討替格瑞洛聯(lián)合阿司匹林對(duì)高齡急性冠脈綜合征（ACS）患者的近期療效及血清指標(biāo)的影響。方法 選擇寶雞市中醫(yī)醫(yī)院2017年1月—2018年8月收治的75例高齡ACS患者，根據(jù)隨機(jī)數(shù)字表法分為觀察組（38例）及對(duì)照組（37例）。對(duì)照組患者口服阿司匹林，100 mg，1次/d。觀察組在對(duì)照組基礎(chǔ)上加用替格瑞洛片，90 mg/次，2次/d。兩組患者均持續(xù)治療3個(gè)月。觀察兩組患者的近期療效、不良心血管事件，比較兩組治療前后的C反應(yīng)蛋白（CRP）、腦鈉肽（BNP）、肌鈣蛋白T（cTnT）、D-二聚體（D-D）水平及不良反應(yīng)發(fā)生率。結(jié)果 治療后，觀察組的總有效率為94.7%，顯著高于的對(duì)照組78.4%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，觀察組的心血管事件發(fā)生率為7.9%，明顯低于對(duì)照組的21.6%，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組的CRP、BNP、cTnT、D-二聚體水平均顯著下降（P<0.05），且觀察組顯著低于對(duì)照組（P<0.05）。兩組不良反應(yīng)對(duì)比無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論 替格瑞洛聯(lián)合阿司匹林對(duì)高齡ACS患者的近期療效顯著，可顯著降低患者的血清指標(biāo)水平，且應(yīng)用安全，心血管不良事件發(fā)生率低，值得臨床推廣應(yīng)用。

Objective To investigate the effect of ticagrelor combined with aspirin on short-term efficacy and serum index in elderly patients with ACS. Methods 75 elderly patients with ACS from January 2017 to August 2018 in Baoji Traditional Chinese Medicine Hospital were chosen and divided into the observation group (38 cases) and control group (37 cases) according to random number table method. Patients in the control group were po asministered with aspirin, 100 mg, once daily. Patients in the observation group were po asministered with Ticagrelor Tablets on the basis of control group, 90 mg/time, twice daily. Patients in two groups were treated for 3 months. After treatment, the short-term efficacy, adverse cardiovascular events were observed, and the CRP, BNP, cTnT, D-D levels before and after treatment in two groups were compared, and adverse reactions rate of two groups were compared. Results After treatment, the total efficacy rate of observation group was 94.7%, which was higher than 78.4% in the control group, and there were differences between two groups (P<0.05). After treatment, the incidence of cardiovascular events of observation group was 7.9%, which was significantly lower than 21.6% in the control group, and there were differences between two groups (P<0.05). After treatment, the levels of CRP, BNP, cTnT, and D-D in two groups were obviously decreased (P<0.05). And the levels of CRP, BNP, cTnT, and D-D in the observation group were significantly lower than those in the control group (P<0.05). The adverse reaction of two groups had no significant difference. Conclusion The short-term effect of ticagrelor combined with aspirin on elderly patients with ACS was significant, could significantly decreased the serum indexes level of patients, and the application is safe, the incidence of cardiovascular adverse events is low, which was worthy of clinical application.